22.10.2014 • News • Private Equity • Biesterfeld • Birger Kuck

Hannover Finanz Takes 28.6% in Biesterfeld Holding

Private equity investor Hannover Finanz Group has taken a 28.6% share of Biesterfeld AG, the holding company for German chemicals and plastics distributor Biesterfeld Group.

The remaining shares will continue to be held by Biesterfeld's wealth management arm, Biesterfeld Vermögensverwaltung.

Since January 2011, Hannover Finanz has been a silent partner in the wealth management company.

Birger Kuck, CEO of the family-owned distributor, said the participation of the private equity company - which goes hand in hand with a capital increase - "allows future growth of the group and sustainably strengthens its equity position."

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Top-Feature

IMCD Deutschland GmbH

Fostering Innovation and Collaboration

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Ecocool GmbH

Transport Logistic: Ecocool Presents Packaging Solutions for Pharmaceutical Transports

Evonik Industries AG

Maximize the Potential of Spent Hydroprocessing Catalysts

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

29.07.2025 • News • Bioprocessing

Hannover Finanz Takes 28.6% in Biesterfeld Holding

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences